Conference Coverage
ReachMD brings you the latest research, announcements, and conversations from the most important medical conferences around the world. Join us on the conference floor with keynote speakers, experts, and opinion leaders.
151-165 of 622
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Project Oncology®Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Ryan Quigley
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Project Oncology®Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Project Oncology®Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Ryan Quigley
Using fMRI to Identify Early Alzheimer’s Disease Subgroups
NeuroFrontiersUsing fMRI to Identify Early Alzheimer’s Disease Subgroups
Hamid Abuwarda, PhD, BS
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
NeuroFrontiersEvaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
Sharon Sha, MD, MS
- advertisement
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart MattersNavigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Jun-ichi Abe
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart MattersTargeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Rethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Heart MattersRethinking Hormones: Testosterone and Estrogen in Women’s Heart Health
Susan Davis
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
- advertisement
Individualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
NeuroFrontiersIndividualized Cognitive Stimulation in Mild Alzheimer’s Disease: Evidence from a Multicenter RCT
Aducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
NeuroFrontiersAducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
Ryan Quigley
Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
NeuroFrontiersEvaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
